DE69638024D1 - Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren - Google Patents

Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Info

Publication number
DE69638024D1
DE69638024D1 DE69638024T DE69638024T DE69638024D1 DE 69638024 D1 DE69638024 D1 DE 69638024D1 DE 69638024 T DE69638024 T DE 69638024T DE 69638024 T DE69638024 T DE 69638024T DE 69638024 D1 DE69638024 D1 DE 69638024D1
Authority
DE
Germany
Prior art keywords
melanoma
antigene
diagnostic
application
therapeutic procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69638024T
Other languages
English (en)
Inventor
Paul F Robbins
Steven A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Application granted granted Critical
Publication of DE69638024D1 publication Critical patent/DE69638024D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69638024T 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren Expired - Fee Related DE69638024D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/370,909 US5843648A (en) 1995-01-10 1995-01-10 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
PCT/US1996/000473 WO1996021734A2 (en) 1995-01-10 1996-01-11 P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods

Publications (1)

Publication Number Publication Date
DE69638024D1 true DE69638024D1 (de) 2009-10-22

Family

ID=23461684

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69638024T Expired - Fee Related DE69638024D1 (de) 1995-01-10 1996-01-11 Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren

Country Status (8)

Country Link
US (1) US5843648A (de)
EP (1) EP0871725B1 (de)
JP (1) JP4223072B2 (de)
AT (1) ATE442439T1 (de)
AU (1) AU705992B2 (de)
CA (1) CA2209990A1 (de)
DE (1) DE69638024D1 (de)
WO (1) WO1996021734A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876972A (en) * 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6872518B2 (en) * 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
JP2003500041A (ja) * 1999-05-25 2003-01-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｍｅｔｈ１およびｍｅｔｈ２ポリヌクレオチドおよびポリペプチド
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
JP2003528605A (ja) * 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US6951720B2 (en) * 2001-05-10 2005-10-04 San Diego State University Foundation Use of phosphorothiolate polynucleotides in ligating nucleic acids
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
CN100577815C (zh) * 2003-05-01 2010-01-06 维里德克斯有限责任公司 手术中的淋巴结检测
NZ591133A (en) 2008-09-02 2012-08-31 Inst Nat Sante Rech Med Novel melanoma antigen peptide and uses thereof
WO2010028672A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5990052A (ja) * 1982-11-16 1984-05-24 Katsu Taniguchi モノクロ−ナル特異抗体を用いたメラノ−マ診断薬
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU3435293A (en) * 1992-01-21 1993-08-03 Ludwig Institute For Cancer Research Method for determining cytolytic T cell precursors
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
ES2172287T4 (es) * 1992-12-22 2003-04-16 Ludwig Inst Cancer Res Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
AU6496094A (en) * 1993-03-31 1994-10-24 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.

Also Published As

Publication number Publication date
US5843648A (en) 1998-12-01
WO1996021734A2 (en) 1996-07-18
WO1996021734A3 (en) 1996-11-28
CA2209990A1 (en) 1996-07-18
EP0871725A2 (de) 1998-10-21
JP4223072B2 (ja) 2009-02-12
AU705992B2 (en) 1999-06-03
EP0871725B1 (de) 2009-09-09
JPH11502405A (ja) 1999-03-02
AU4755496A (en) 1996-07-31
ATE442439T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
EP1630229A3 (de) Melanoma Antigene
EP2311952A3 (de) Antikörper gegen MART-1 Protein oder Fragmenten davon
TR199801722T2 (xx) Peptit imm�nojenler.
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
CA2290485A1 (en) Method for the production of non-immunogenic proteins
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE69737125D1 (de) Streptococcus pneumoniae antigene und impfstoffe
ID28299A (id) Protein-protein reseptor seperti toll manusia metoda-metoda dan reagen-reagen yang berhubungan
CU22615A1 (es) Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
BG101024A (bg) Моноклонално антитяло срещу сd44v6
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AR033832A1 (es) Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
DK0610335T3 (da) Fremgangsmåder til udformning af rekombitope peptider
RU94046414A (ru) Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав
BR9713450A (pt) Quimiocinas de mamìfero
ATE86633T1 (de) Snrnp-a-antigen und fragmente davon.
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee